
Metis Techbio-p
7666.HKHKSEHealthcareBiotechnology
Latest quote
HK$13.53
−HK$0.71 · -4.99%
7666.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteMetis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Tsai-Ta Lai
- Listed since
- May 13, 2026
- Employees
- 5
Market position
Day range
Current HK$13.53
52-week range
Current HK$13.53
- Open
- HK$14.79
- Previous close
- HK$14.24
- Volume
- 3.97M
- 0.85× average
- Average volume
- 4.68M
- Average daily volume
- Market cap
- 16B HKD
- Beta
- 2.15
- Market reference 1
- 50-day average
- HK$12.3898
- +9.20% above average
- 200-day average
- HK$13.742
- -1.54% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -37.36×
- P/B (TTM)
- 13.71×
- P/S (TTM)
- 139.56×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 66.01%
- Operating margin
- -367.07%
- Net margin
- -373.18%
Financial health
- Debt / equity
- 0.13×
Earnings
- Latest fiscal-year EPS
- -0.046
- FY2025
- Latest fiscal-year revenue
- 14.63M HKD
- FY2025 · +6974.88% year over year
- Next fiscal-year EPS consensus
- -0.087
- FY2026 · 2 analysts
- Next fiscal-year revenue consensus
- 428.41M HKD
- FY2026 · 3 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
7666.HK peers
Continue in GoAI
Research 7666.HKresearch.disclaimer





